Revelation Biosciences, Inc. (REVB) Stock Price & Analysis

Revelation Biosciences, Inc. (REVB) rose 0.00% to USD 1.01 as of September 8, 2026 at 06:55 UTC, according to Nexqual real-time market data.

REVB last closed at USD 1.01; the session ranged USD 0.99–1.04 on volume of 7,800 shares. Market capitalization is —, with a 52-week range of USD 0.88–11.6 (NCM). Source: Nexqual, September 8, 2026 at 06:55 UTC.

Key Statistics (as of September 8, 2026 at 06:55 UTC)

Technical Analysis (REVB)

Nexqual's technical model rates REVB "STRONG SELL" based on 0 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 06:55 UTC.

From Revelation Biosciences, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• We also rely on trade secret protection of our confidential information and know-how relating to our proprietary technology, platforms, and Product Candidates.   18   As of February 23, 2026, our patent portfolio includes one patent family directed to MPLA formulations, including Gemini.
• Potential Future Applications for Gemini The Gemini Platform Our current therapeutic programs are based on our proprietary Gemini formulation of PHAD ® , a synthetic version of monophosphoryl lipid A ("MPLA") with a well-established biology.
• The CDC says Medicare in 2015 alone had an annual expenditure of over $10 billion and growing for AKI, with spending for AKI related costs of approximately $42,077 per patient.
• For Product Candidates regulated under the FD&C Act, FDA must approve a New Drug Application ("NDA").

Partnerships

• Revelation met with FDA at the end of 2025 and obtained agreement on a single Phase 2/3 adaptive design study with a primary composite endpoint of death and/or dialysis for submission of a new drug application (NDA).
• P-values generated using two-tailed t-test with alpha at 5%.   16   Development Plans AKI Revelation met with FDA at the end of 2025 and obtained agreement on a single Phase 2/3 adaptive design study comprising approximately 300 patients with AKI and a primary composite endpoint of death and/or need for dialysis, the data from which can be used for submission of a new drug application (NDA).

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:55 UTC. This page is informational and not investment advice.